|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
none reported
|
|
gptkbp:CEO
|
Scott_Wolchko
|
|
gptkbp:clinicalTrials
|
multiple
Phase 1
clinical trials
Phase 2
Phase 3
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:employees
|
over 100
|
|
gptkbp:financials
|
publicly traded
|
|
gptkbp:focus
|
cell therapy
|
|
gptkbp:focusArea
|
cancer treatment
|
|
gptkbp:founded
|
2012
|
|
gptkbp:founder
|
John_F._McCarty
|
|
gptkbp:headCoach
|
Dr._Michael_T._Hellerstein
|
|
gptkbp:headquarters
|
gptkb:San_Diego,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fate Therapeutics, Inc.
|
|
gptkbp:investmentFocus
|
various venture capital firms
over $200 million raised
|
|
gptkbp:leads
|
FT596
FT819
FT516
|
|
gptkbp:market
|
approximately $500 million
|
|
gptkbp:mission
|
transforming the treatment of cancer and immune disorders.
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:CureVac
gptkb:Takeda_Pharmaceutical_Company
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Celerion
Novartis
|
|
gptkbp:regulatoryCompliance
|
various products in development
|
|
gptkbp:research_areas
|
solid tumors
hematologic malignancies
|
|
gptkbp:researchAreas
|
immuno-oncology
|
|
gptkbp:stockSymbol
|
FATE
|
|
gptkbp:technology
|
iPSC-derived cell therapies
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:tributaryOf
|
cell-based therapies
|
|
gptkbp:type
|
public company
|
|
gptkbp:website
|
www.fatetherapeutics.com
|